News & Updates

Show Multimedia Only

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

15 Sep 2022 by

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

15 Sep 2022

Monkeypox now a global health emergency

15 Sep 2022 by

The WHO has declared the monkeypox outbreak a global health emergency – the agency’s highest level of alert – following a worldwide upsurge in cases. There are currently 5 deaths tied to the outbreak – Spain has seen two deaths, India has one, while Brazil and Ecuador have one each. As of the latest reports, cases have crossed 38,800 in 80 countries where monkeypox is not endemic.

15 Sep 2022

Roflumilast shows treatment potential for seborrheic dermatitis

15 Sep 2022 by

In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).

15 Sep 2022

Original New Drug Application Approvals by US FDA (01 - 15 September 2022)

15 Sep 2022

New drug applications approved by US FDA as of 01 - 15 September 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

15 Sep 2022

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?

14 Sep 2022 by

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

14 Sep 2022

MRNA booster shot durably bolsters defenses against severe COVID-19

14 Sep 2022 by

Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.

14 Sep 2022

Phase II data reveal treatment potential of pegozafermin for severe hypertriglyceridaemia

14 Sep 2022 by

The phase II ENTRIGUE trial presented at ESC 2022 showed the potential of pegozafermin to improve triglyceride levels and other lipid-related metrics in individuals with severe hypertriglyceridaemia.

14 Sep 2022

Prescription meds tied to nutritional status in CKD

14 Sep 2022

Patients with chronic kidney disease (CKD) often need to take several prescription medicines concurrently, which in turn appears to worsen nutritional status, a recent study has found.

14 Sep 2022

Nicorandil improves PCI outcomes in STEMI patients

14 Sep 2022

In patients with ST‐segment–elevation myocardial infarction (STEMI), treatment with nicorandil prior to undergoing primary percutaneous coronary intervention (PCI) may result in improved myocardial perfusion grade, increased left ventricular ejection fraction, and reduced myocardial infarct size, according to data from the CHANGE* study.

14 Sep 2022

Ivermectin not superior to placebo in mild COVID-19

13 Sep 2022 by

Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.

13 Sep 2022

News & Updates

Showing Pharmacy articles

Showing

Specialty:

First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status

Monkeypox now a global health emergency

Roflumilast shows treatment potential for seborrheic dermatitis

Original New Drug Application Approvals by US FDA (01 - 15 September 2022)

Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?

MRNA booster shot durably bolsters defenses against severe COVID-19

Phase II data reveal treatment potential of pegozafermin for severe hypertriglyceridaemia

Prescription meds tied to nutritional status in CKD

Nicorandil improves PCI outcomes in STEMI patients

Ivermectin not superior to placebo in mild COVID-19